Wyeth Seeks Approval To Launch 2 Drugs In Japan By 2007 End (Japan)
This article was originally published in PharmAsia News
Executive Summary
Wyeth is seeking marketing approval to introduce two prescription drugs in Japan. The company will file a new drug application with the Japanese government for Tygacil and Viviant by the end of this year. Viviant is used for osteoporosis, while Tygacil is used to treat pneumonia and other infections. The new drug launches are part of Wyeth's aim to raise sales in Japan to $1 billion by 2010, nearly double that of 2006. (Click here for more - May Require Paid Subscription
You may also be interested in...
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.
Demi Moore’s Wonderbelly Antacid Investment Lands Supporting Role In Her Promotional Posts
Wonderbelly Antacids “free from” ad claims work but failing to disclose Demi Moore is an investor in her promotions doesn’t, NAD says. Dakota Nutrition fails again on NAD’s test of its testing for elderberry in its supplements.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.